At Sage, our mission is to make medicines that matter so people can get better, sooner.
Our Core Values
The Sage Medical Hub is a resource for licensed HCPs and other key stakeholders that provides access to Sage’s Global Medical Affairs team.
Visitors to the hub may:
Modulating GABA and NMDA Receptors
We focus our research and development efforts on modulation of GABA and NMDA receptors—two critical neurotransmitter systems in the brain. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS); NMDA is the major excitatory pathway. Both contribute significantly to regulating CNS function. Dysfunction in these two systems is known to be at the core of numerous psychiatric and neurological disorders. Our novel investigational compounds are intended to alter activity at these receptors by working with the brain’s natural signaling mechanisms. We believe compounds that are designed to restore normal balance between excitatory and inhibitory signals within the brain have the potential to treat a range of brain health disorders associated with a variety of cognitive, neurological, and behavioral symptoms.
We’re conducting clinical trials in several brain health disorders where there is a need for additional treatment options.
When about 1 in 9 moms suffers from postpartum depression (PPD), Each.Day.Matters.
ZULRESSO (brexanolone) is the first and only FDA-approved medicine specifically for postpartum depression in adults.
In clinical studies, moms who took ZULRESSO experienced a greater improvement in symptoms of postpartum depression vs placebo in 2.5 days. Symptoms were measured at the beginning of treatment using a standard depression scale and again at the end of treatment.
The human brain is the most complex organ of the human body. It is made up of an integrated network of approximately 100 billion nerve cells called neurons, connected in complex electrical circuits to communicate. Brain health and function depend on the interaction of these circuits. Navigating these complex circuits is a challenge, but a welcome opportunity for the teams at Sage as we seek to develop novel medicines.
We are focusing on disorders where there is a high unmet need for additional treatment options. Sage is working to understand the underlying mechanisms for numerous disorders of the brain and central nervous system (CNS) to help us develop therapies that may address current treatment gaps for patients. We focus our research and development efforts on modulation of GABA and NMDA receptors, two critical neurotransmitter systems that have responsibility for information flow within the intricate circuits of the brain and central nervous system.
The Montana Psychiatry Conference makes every attempt to provide accurate and timely content available for users. Neither MPC nor third-party content providers are responsible or liable for any such content, including advertising, products or other materials available through third party sites.